BRIEF-AveXis Announces First Patient Dosed In Phase 3 Trial Of AVXS-101 In Pre-Symptomatic SMA Types 1, 2 And 3
April 25, 2018 at 08:10 AM EDT
* AVEXIS ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 TRIAL OF AVXS-101 IN PRE-SYMPTOMATIC SMA TYPES 1, 2 AND 3 Source text for Eikon: Further company coverage:
